NawlinsAg01 said:

---

Wendy 1990 said:

---

Laura Ingraham is ripping this study. The drug was given to very ill patients in the cytokine storm in this study. The control group was given the Z pack!

---

Which study are you referencing?

---

barnyard1996 said:

---

2PacShakur said:

---

barnyard1996 said:

---

NawlinsAg01 said:

---

Wendy 1990 said:

---

Laura Ingraham is ripping this study. The drug was given to very ill patients in the cytokine storm in this study. The control group was given the Z pack!

---

Which study are you referencing?

---

Some VA study

---

I don't think Laura understands what's a control. Just look at the headers for table 1 or 2, they describe each study arm: https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1.full.pdf

---

Its was segment designed to provide political cover.

---

rayneag said:

---

barnyard1996 said:

---

2PacShakur said:

---

barnyard1996 said:

---

NawlinsAg01 said:

---

Wendy 1990 said:

---

Laura Ingraham is ripping this study. The drug was given to very ill patients in the cytokine storm in this study. The control group was given the Z pack!

---

Which study are you referencing?

---

Some VA study

---

I don't think Laura understands what's a control. Just look at the headers for table 1 or 2, they describe each study arm: https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1.full.pdf

---

Its was segment designed to provide political cover.

---

What is Dr. Raoult's motive?

https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Response-to-Magagnoli.pdf

---

DadHammer said:

---

RESULTS:
Of the 636 symptomatic outpatients, 412 started treatment with hydroxychloroquine and azithromycin and 224 refused medications (control group). Need for hospitalization was 1.9% in the treatment group and 5.4% in the control group (2.8 times greater) and number needed to treat was 28 (NNT = 28).
In those who started treatment before versus after the seventh day of symptoms, the need for hospitalization was 1.17% and 3.2%, respectively.
CONCLUSION:
Empirical treatment with hydroxychloroquine associated with azithromycin for suspected cases of COVID-19 infection reduces the need for hospitalization (p< 0.001).



https://static.poder360.com.br/2020/04/2020.04.15-journal-manuscript-final.pdf

---

cone said:

---

that's a pretty good little study

especially liked the telemedicine diagnostic approach. curious how and when they got the imaging results to conclude COVID probable.

still it does seem to bolster the early use helps reduce severity anecdotes

---

cone said:

---

of course that's a problem

but the tests are also unreliable

and CT seems to be the actual way to get a definitive "you have COVID" diagnosis

---

culdeus said:

---

cone said:

---

of course that's a problem

but the tests are also unreliable

and CT seems to be the actual way to get a definitive "you have COVID" diagnosis

---

I'm not a doctor, I find the above statement sketchy. I feel like 80-90% of patients would not show on a CT scan at any point.

The CT was for those that went to the hospital. The idea here was to keep lightly symptomatic people away from the hospital altogether.

I would hesitate to use this information for anything, Brazil has a low case count. You need to do science with the right conditions in mind. If anything you could probably use this to say a medicine route prevents hospital visits, and subsequent infections of non-impacted people.

Other than that the setup of the study isn't really viable and there's a reason it has been more or less buried for two weeks (on dropbox).

I suppose it's good news to the state of Utah who is desperate to get rid of piles and piles of this stuff..

---

FCBlitz said:

---

culdeus said:

---

cone said:

---

of course that's a problem

but the tests are also unreliable

and CT seems to be the actual way to get a definitive "you have COVID" diagnosis

---

I'm not a doctor, I find the above statement sketchy. I feel like 80-90% of patients would not show on a CT scan at any point.

The CT was for those that went to the hospital. The idea here was to keep lightly symptomatic people away from the hospital altogether.

I would hesitate to use this information for anything, Brazil has a low case count. You need to do science with the right conditions in mind. If anything you could probably use this to say a medicine route prevents hospital visits, and subsequent infections of non-impacted people.

Other than that the setup of the study isn't really viable and there's a reason it has been more or less buried for two weeks (on dropbox).

I suppose it's good news to the state of Utah who is desperate to get rid of piles and piles of this stuff..

---

Look up University of Michigan study on using CT scans for COVID19. They said COVID19 in the lungs look like broken glass. Later in the week I saw a CT scan and it did look like broken glass

---

Quote:

---

I feel like 80-90% of patients would not show on a CT scan at any point.

---

DadHammer said:

---

Infectious disease expert slams study that panned hydroxychloroquine as COVID-19 treatment: 'It's a sham'

https://www.foxnews.com/media/dr-stephen-smith-study-hydroxychloroquine-coronavirus-treatment

It's a shame the way this is being handled. Why can't we just get some honest people and do real trials? We could have done this a month ago. Unbelievable.

My Dr. says it's working and he will prescribe it to anyone he thinks it will help. I am going with on the ground results from a real Dr. in the field. To heck with the rest of them.

---

Quote:

---

But the truth is that there's a pretty typical dosage for both HCL and AZ, and it's probably unlikely any of those docs were deviating too far.

---

Quote:

---

Multiple prospective, randomized trials of hydroxychloroquine are now underway and will, in due course, provide valuable information about safety and efficacy. However, given its increasingly widespread use, not only as therapy but also as prophylaxis for Covid-19, there is a great and immediate need to obtain insights into the clinical outcomes among patients currently treated with hydroxychloroquine, particularly because of the non-negligible toxicities associated with its use.

Therefore, we conducted a retrospective analysis of patients hospitalized with Covid-19 in all the Veterans Health Administration medical centers across the United States to analyze the associations between hydroxychloroquine and azithromycin use and clinical outcomes. The findings of this nationwide study of one of the most complete national datasets in the United States can accelerate our understanding of the outcomes of these drugs in Covid-19 while we await the results of the ongoing prospective trials.

....

Our study has certain limitations including those inherent to all retrospective analyses such as non-randomization of treatments. We did, however adjust for a large number of Covid19-relevant confounders including comorbidities, medications, clinical and laboratory abnormalities. Despite propensity score adjustment for a large number of relevant confounders, we cannot rule out the possibility of selection bias or residual confounding. Our study cohort comprised only men whose median age was over 65 years. Therefore, the results may not necessarily reflect outcomes in women or in younger hospitalized populations, nor can they be extrapolated to pediatric patients.

Our findings may also be influenced by the demographic composition of patients in our cohort, the majority of whom were black. Disproportionately higher rates of Covid-19-related hospitalization among the black population have also been reported in the United States as a whole.

Our study also has certain strengths. Because we studied data from a comprehensive electronic medical record rather than from an administrative health insurance claims database, we used rigorously identified covariates and outcomes. We studied patients in an integrated national healthcare system; therefore, the data are less susceptible to biases of single-center or regional studies. Data from ongoing, randomized controlled studies will prove informative when they emerge. Until then, the findings from this retrospective study suggest caution in using hydroxychloroquine in hospitalized Covid-19 patients, particularly when not combined with azithromycin

---

Quote:

---

...hydroxychloroquine, with or without azithromycin, was more likely to be prescribed to patients with more severe disease, as assessed by baseline ventilatory status and metabolic and hematologic parameters. Thus, as expected, increased mortality was observed in patients treated with hydroxychloroquine, both with and without azithromycin. Nevertheless, the increased risk of overall mortality in the hydroxychloroquine-only group persisted after adjusting for the propensity of being treated with the drug. That there was no increased risk of ventilation in the hydroxychloroquine-only group suggests that mortality in this group might be attributable to drug effects on or dysfunction in non-respiratory vital organ systems.

---

VaultingChemist said:

---

Morocco started HCQ treatments two weeks before Algeria, and it is surprisingly consistent with the reaction in this chart.

---